Polymer formulations of CETP inhibitors

摘要

Disclosed herein are pharmaceutical compositions comprising: a) a CETP inhibiting oxazolidinone compound of formula Ii, or a pharmaceutically acceptable salt thereof wherein the substituents are as defined within the specification; b) a concentration-enhancing polymer selected from the group consisting of hydroxypropyl methyl cellulose acetate succinate (HPMCAS), hydroxypropyl methyl cellulose phthalate (HPMCP), cellulose acetate phthalate (CAP), cellulose acetate trimellitate (CAT), methyl cellulose acetate phthalate, hydroxypropyl cellulose acetate phthalate, cellulose acetate terephthalate, cellulose acetate isophthalate, polyvinylpyrrolidinone, and polyvinylpyrrolidinone-polyvinylacttate copolymers; and c) optionally one or more surfactants selected from the group consisting of sodium dodecyl sulphate and one or more noninoic surfactants selected from a)sorbitan fatty acid esters, b) polyoxyethylene sorbitan fatty acid esters, c) polyoxyethylene castor oils, d) polyoxyethylene hydrogenated castor oils, and e) vitamin E TPGS; and mixtures thereof. Such compositions are useful in raising HDL-cholesterol in a patient.